Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic

Sanofi has decided to discontinue the development of SAR448272, a STAT6 degrader drug developed in partnership with Nurix Therapeutics. This decision comes shortly after the drug entered the clinic, with coverage from Fierce Biotech noting the termination occurred just two months after that milestone. According to Reuters and Yahoo Finance, the program was focused on treating autoimmune diseases. The abrupt cessation of the project has led to a significant downturn for Nurix Therapeutics (NASDAQ: NRIX), with stock prices falling sharply following the announcement. Financial reporting from FirstWord Pharma and Seeking Alpha emphasizes the severe impact on Nurix, describing the stock as having cratered.

Kalkine.ca reports that Nurix saw a decline of 40.80%, a drop that occurred despite the company receiving a USD 700 million payment from Roche. Other outlets, including BioPharma Dive and Investor's Business Daily, highlight the contrast between the two partners, noting that while the eczema-focused partner Nurix experienced a crash, Sanofi has seen a breakout in its own market performance. To understand the current stakes, readers must note that STAT6 degraders are designed to target specific proteins involved in immune responses. The collaboration between Sanofi and Nurix was aimed at leveraging this technology for autoimmune conditions, including eczema. The speed of the discontinuation—occurring only two months into clinical testing—suggests a rapid strategic shift or a specific discovery during the early clinical phase that prompted Sanofi to bin the project entirely.

Moving forward, observers will monitor how Nurix manages its remaining pipeline and the utilization of the USD 700 million payment from Roche to offset the loss of the Sanofi partnership. Coverage does not yet specify the exact clinical reasons for the discontinuation of SAR448272. Market analysts will likely watch for further updates from Nurix regarding its strategic direction and whether any other partnerships are affected by the termination of the STAT6 degrader program.